文献速递毛发、甲与色素性疾病皮肤肿瘤

ABCB1基因变异与乳腺癌患者持续性化疗脱发的关联

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该遗传关联研究纳入215例接受多西他赛化疗的乳腺癌女性,发现ABCB1调控变异rs1202179与持续性化疗诱导脱发(pCIA)风险相关,合并比值比4.05(95%CI 2.46-6.67,P=3.946×10⁻⁸),且风险等位基因与ABCB1表达降低相关。

要点

  • ABCB1 rs1202179与pCIA风险显著关联,合并OR 4.05。
  • 风险等位基因与ABCB1 mRNA表达降低相关(P=1.64×10⁻²⁰)。
  • 该变异位于增强子元件,与ABCB1启动子相互作用。

核心结论

  • 首次发现ABCB1基因调控变异与多西他赛化疗后pCIA发生相关。

研究设计与样本

  • 遗传关联研究,回顾性招募215例接受多西他赛化疗的乳腺癌女性,来自西班牙3个肿瘤科,2005-2018年。
  • 发现阶段173例,验证阶段42例;严重pCIA定义为治疗结束18个月后头皮毛发未恢复(CTCAE v3.0 2级)。

主要发现

  • 发现阶段ABCB1遗传变异与pCIA风险相关,rs1202179位于增强子元件,与ABCB1启动子相互作用。
  • 验证队列中rs1202179与pCIA关联的合并OR为4.05(95%CI 2.46-6.67,P=3.946×10⁻⁸)。
  • rs1202179与ABCB1 mRNA表达相关,风险等位基因携带者ABCB1表达水平降低(P=1.64×10⁻²⁰)。

关键数值与推荐

  • 严重pCIA定义:治疗结束18个月或以上无头皮毛发恢复(CTCAE v3.0 2级)。
  • 对照定义:多西他赛治疗结束12个月后无残留脱发迹象。

临床怎么用

  • ABCB1 rs1202179可能作为pCIA风险分层标志物,为个体化治疗提供线索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Persistent chemotherapy-induced alopecia (pCIA) has been recently described in patients with breast cancer and in its most severe form occurs in up to 10% of these patients. Genetic risk factors associated with pCIA have not been adequately explored. OBJECTIVE: To identify genetic variants associated with pCIA. DESIGN, SETTING, AND PARTICIPANTS: In this genetic association study, 215 women with breast cancer treated with docetaxel-based chemotherapy with a follow-up of 1.5 to 10 years after the end of the treatment were recruited retrospectively through 3 hospital oncology units across Spain between 2005 and 2018. Severe pCIA was defined as lack of scalp hair recovery (Common Terminology Criteria for Adverse Events, version 3.0, grade 2) 18 months or more after the end of treatment. Patients with grade 2 pCIA were selected as cases, and those with no sign of residual alopecia 12 months after the end of docetaxel treatment were selected as controls. A genome-wide association study in a discovery phase was conducted, and logistic regression was used to identify variants associated with the risk to develop this adverse effect. The validity of the association was addressed through a replication phase. EXPOSURES: Docetaxel-based chemotherapy. MAIN OUTCOMES AND MEASURES: Genotypes of single-nucleotide variants associated with pCIA. RESULTS: In total, 215 women with breast cancer (median age, 51.6 years; interquartile range, 44-60 years) were recruited (173 patients for the discovery phase and 42 patients for the replication phase). In the discovery phase, ABCB1 genetic variants were associated with risk to develop pCIA. In particular, single-nucleotide variation rs1202179, a regulatory variant located in an enhancer element that interacts with the ABCB1 promoter, was associated with the occurrence of pCIA. This finding was validated in the replication cohort (combined odds ratio, 4.05; 95% CI, 2.46-6.67; P = 3.946 × 10-8). This variant is associated with ABCB1 mRNA expression, and the risk allele was associated with decreased ABCB1 expression levels (P = 1.64 × 10-20). CONCLUSIONS AND RELEVANCE: This is the first study, to our knowledge, that identifies an association between a regulatory variant in the ABCB1 gene and the occurrence of pCIA in patients with breast cancer who were treated with docetaxel-based therapies. This finding suggests an important insight into the biological mechanisms underlying pCIA and opens the opportunity to explore personalized treatment of these patients.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Núñez-Torres R, Martín M, García-Sáenz JÁ, et al. Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer. JAMA Dermatol. 2020. PMID: 32756886. doi:10.1001/jamadermatol.2020.1867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。